CEO James D. Swift elected to Pediatrix board after director Roger J. Medel resigns

Pediatrix Medical Group, Inc.

Roger J. Medel resigned from the Board effective March 7, 2023; no disagreement with the Company.
CEO James D. Swift elected to Board to fill the vacancy created by Medel's resignation.
Swift receives no additional compensation for board service beyond his CEO pay.
Medel's resignation and Swift's election occurred on March 8, 2023.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James D. Swift

Director

MD · Pediatrix Medical Group, Inc.

Effective: 2023-03-08
Filed: March 8, 2023, 6:59 PM ET

elected James D. Swift, M.D., the Company’s Chief Executive Officer, to the Board to fill a vacancy created by the resignation of Roger J. Medel M.D.

Departed

Roger J. Medel

Director

MD · Pediatrix Medical Group, Inc.

Effective: 2023-03-07
Successor: James D. Swift
Filed: March 8, 2023, 6:59 PM ET

who resigned from the Board effective March 7, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James D. Swift was elected as Director at Pediatrix Medical Group, Inc..

Action: elected
Role: Director

Exact text from the filing

elected James D. Swift, M.D., the Company’s Chief Executive Officer, to the Board to fill a vacancy created by the resignation of Roger J. Medel M.D.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Roger J. Medel resigned as Director at Pediatrix Medical Group, Inc..

Action: resigned
Role: Director

Exact text from the filing

who resigned from the Board effective March 7, 2023.

View on SEC.gov

Pediatrix Medical Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006748

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.